Allergy and Immunology Teaching Series presentation by Seppi Lin, MD, Vice President, Head of OMNI Early Clinical Development, Genentech

At the conclusion of this presentation, attendees should be able to:
1. Distinguish between objectives of Phase 2 and Phase 3 studies in asthma drug development
2. Have a working knowledge of advantages and limitations of composite endpoints such as CompEx in asthma.
3. Have comparative knowledge of other endpoints and study designs used in early clinical development for asthma.

свернуть